In this report, we cover catalysts from 21 drugs, devices and diagnostics expected to occur in Q2 2016. We have also included a list of Large Impact catalysts in the drug and device/diagnostic areas through Q2 2016 from our sister product, CatalystTracker. In addition, each drug’s likelihood of Phase/PDUFA review success and overall Likelihood of Approval (LOA) given their particular phase, drug class, and disease group are provided.

Our Early 2016 Outlook Report highlighted several high- impact catalysts. The results of these catalysts can be found on Page 5 of this report. Biomedtracker Likelihood of Approval (LOA) opinions successfully predicted 78% of catalyst outcomes that occurred in Early 2016.

For the full report, please download the PDF version at the top of this page. Additionally, the catalyst calendars are provided in Excel by downloading the supplemental material above.

For our disclosures, please read the BioMedTracker Research Standards.